Abstract:Calcium/calmodulin‐dependent protein kinase kinase 2 (CaMKK2) and mitochondrial sodium/calcium exchanger protein (NCLX) are key regulatory factors in calcium homeostasis. Finding natural drugs that target regulators of calcium homeostasis is critical. Dihydroartemisinin (DHA) is considered to have anticancer effects. The present study aimed to investigate the mechanism of DHA in regulating liver cancer migration and invasion. The present study used HepG2 and HuH‐7 cells and overexpressed CaMKK2 and knocked down CaMKK2 and NCLX. The antiproliferative activity of DHA on liver cancer cells was assessed through colony formation and EdU assays. Cell apoptosis was detected through YO‐PRO‐1/PI staining. The levels of reactive oxygen species (ROS) were measured using a ROS detection kit (DCFH‐DA fluorescent probe). Cell migratory and invasive abilities were examined using wound healing and Transwell assays. The ATP production of liver cancer cells was detected using ATP fluorescent probes. Cell microfilaments were monitored for changes using Actin‐Tracker Green‐488. The effects of DHA on the expression of CaMKK2, NCLX, sodium/potassium‐transporting ATPase subunit α‐1 (ATP1A1) and ATP synthase subunit d, mitochondrial (ATP5H) were determined by western blotting and reverse transcription‐quantitative PCR. The results revealed that DHA significantly inhibited proliferation, reduced ROS levels and promoted apoptosis in liver cancer cells. CaMKK2 overexpression significantly enhanced the invasive and migratory ability of liver cancer cells, whereas DHA inhibited the pro‐migratory effects of CaMKK2 overexpression. DHA significantly reduced the mitochondrial ATP production and altered the arrangement of microfilaments in liver cancer cells. In addition, DHA significantly decreased the expression of CaMKK2, NCLX, ATP1A1 and ATP5H. Furthermore, by knockdown experiments of NCLX the results demonstrated that CaMKK2 downregulated the expression of ATP1A1 and ATP5H in liver cancer cells through NCLX. In conclusion, DHA may reduce ATP synthase production via the CaMKK2/NCLX signaling pathway to inhibit the invasive phenotype of liver cancer cells. It is essential to further investigate the effectiveness of DHA in the anticancer mechanism of liver cancer cells.

Dihydroartemisinin Regulates Self-Renewal of Human Melanoma-Initiating Cells by Targeting PKM2/LDHA Related Glycolysis

Dihydroartemisinin Inhibits Melanoma by Regulating CTL/Treg Anti-Tumor Immunity and STAT3-mediated Apoptosis Via IL-10 Dependent Manner

Inhibitory Effect of Dihydroartemisinin on the Proliferation and Migration of Melanoma Cells and Experimental Lung Metastasis From Melanoma in Mice

Dihydroartemisinin inhibits melanoma migration and metastasis by affecting angiogenesis

Dihydroartemisinin sensitizes Lewis lung carcinoma cells to carboplatin therapy via p38 mitogen-activated protein kinase activation.

Dihydroartemisinin Exhibits Anti-Glioma Stem Cell Activity Through Inhibiting P-Akt and Activating Caspase-3.

Interruption of the MEK/ERK Signaling Cascade Promotes Dihydroartemisinin-Induced Apoptosis in Vitro and in Vivo

Dihydroartemisinin Suppresses Pancreatic Cancer Cells Via a Microrna-Mrna Regulatory Network

Dihydroartemisinin suppresses glioma growth by repressing ERRα-mediated mitochondrial biogenesis

Dihydroartemisinin inhibits liver cancer cell migration and invasion by reducing ATP synthase production through CaMKK2/NCLX

Dihydroartemisinin Inhibits the Raf/ERK/MEK and PI3K/AKT Pathways in Glioma Cells.

Dihydroartemisinin Inhibits the Proliferation of Esophageal Squamous Cell Carcinoma Partially by Targeting AKT1 and p70S6K

AKT Axis, miR-21, and RECK Play Pivotal Roles in Dihydroartemisinin Killing Malignant Glioma Cells.

Dihydroartemisinin Inhibits Growth of Pancreatic Cancer Cells in Vitro and in Vivo

Dihydroartemisinin Induces Autophagy and Inhibits the Growth of Iron-Loaded Human Myeloid Leukemia K562 Cells Via ROS Toxicity.

Dihydroartemisinin inhibited stem cell-like properties and enhanced oxaliplatin sensitivity of colorectal cancer via AKT/mTOR signaling.

Dihydroartemisinin Modulates Apoptosis and Autophagy in Multiple Myeloma Through the P38/MAPK and Wnt/β-Catenin Signaling Pathways.

Dihydroartemisinin inhibits angiogenesis in breast cancer via regulating VEGF and MMP-2/-9

Dihydroartemisinin inhibits Lewis Lung carcinoma progression by inducing macrophages M1 polarization via AKT/mTOR pathway

Dihydroartemisinin Exhibits Antitumor Activity Toward Hepatocellular Carcinoma in Vitro and in Vivo.

Repurposing Dihydroartemisinin to Combat Oral Squamous Cell Carcinoma, Associated with Mitochondrial Dysfunction and Oxidative Stress